None-hydrophobic Compounds for Use in Treating Metastasis And/or Cartilage Defect

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes novel non-hydrophobic compounds and their pharmaceutical compositions that inhibit the dimerization of the melanoma inhibitory activity (MIA) protein. By blocking MIA dimerization, these compounds are useful in preventing and treating metastasis deriving from MIA-expressing tumors (such as melanoma, breast cancer, glioma, pancreatic cancer, and colon cancer) as well as in treating cartilage defects, since MIA dimerization suppresses cartilage regeneration. The invention offers both specific compounds and general classes, and the compounds can be administered orally, alone, or in combination with established chemotherapeutic agents.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of metastatic melanoma and other MIA-expressing cancers (e.g., breast, pancreas, glioma, colon) to prevent or reduce secondary tumor formation.
• Therapeutic intervention in cartilage degenerative diseases such as osteoarthritis, rheumatoid arthritis, joint degeneration, and injuries resulting in cartilage defects.
• Adjuvant therapy to classical chemotherapy regimens for enhanced efficacy and broader treatment outcomes in cancer patients.
• Use in pharmaceutical compositions as oral drugs targeted at MIA protein dimerization, improving patient compliance.
• Potential combination treatments for simultaneous targeting of metastatic spread and cartilage repair in complex clinical scenarios.

BenefitsContent extracted from patent full text and abstract with AI.

• Targets the extracellular MIA protein dimerization pathway, a critical mechanism in metastasis and cartilage degeneration, offering a novel therapeutic approach.
• Enables oral administration, which is typically not feasible for peptide-based MIA inhibitors, improving patient convenience and compliance.
• Demonstrates specificity for tumor cells and impaired cartilage regeneration, with negligible negative effects on healthy cell lines such as fibroblasts and kidney cells.
• Can be used in synergy with established chemotherapy drugs, potentially improving overall therapeutic efficacy and outcomes.
• Applicable to a wide range of cancers and cartilage disorders, broadening the clinical utility of the approach.
• Non-hydrophobic compound profiles are more compatible with drug-likeness, pharmacokinetics, and systemic administration.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention is directed to compounds, tautomers, stereoisomers, and chemically modified compounds thereof, and their use in preventing and/or treating tumors of metastasis and/or cartilage defect, and to a pharmaceutical composition comprising such compound.